The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Protein concentration is above or equal to 0.05 mg/ml.
Concentration information loading...
Preparation and Storage
Stability and Storage
Shipped on dry ice. Upon delivery aliquot and store at -80ºC. Avoid freeze / thaw cycles.
pH: 8.00 Constituents: 0.31% Glutathione, 0.79% Tris HCl
E3 ubiquitin protein ligase MYLIP
E3 ubiquitin-protein ligase MYLIP
Inducible degrader of the LDL-receptor
Myosin regulatory light chain interacting protein
E3 ubiquitin-protein ligase that mediates ubiquitination and subsequent proteasomal degradation of myosin regulatory light chain (MRLC), LDLR, VLDLR and LRP8. Proteasomal degradation of MRLC leads to inhibit neurite outgrowth in presence of NGF by counteracting the stabilization of MRLC by saposin-like protein (CNPY2/MSAP) and reducing CNPY2-stimulated neurite outgrowth. Acts as a sterol-dependent inhibitor of cellular cholesterol uptake by mediating ubiquitination and subsequent degradation of LDLR.
Protein modification; protein ubiquitination.
Contains 1 FERM domain. Contains 1 RING-type zinc finger.
Expressed in fetal tissues and higher levels were detected in placenta and fetal lung.
The RING domain mediates ubiquitination and the neurite outgrowth inhibitory activity.